{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T14:06:06Z","timestamp":1785420366450,"version":"3.56.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T00:00:00Z","timestamp":1617667200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T00:00:00Z","timestamp":1617667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008363","name":"Kr\u00e6ftens Bek\u00e6mpelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007505","name":"Kirsten og Freddy Johansens Fond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007505","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007371","name":"Svend Andersen Fonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007371","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>As an immune evasion and survival strategy, the<jats:italic>Plasmodium falciparum<\/jats:italic>malaria parasite has evolved a protein named VAR2CSA. This protein mediates sequestration of infected red blood cells in the placenta through the interaction with a unique carbohydrate abundantly and exclusively present in the placenta. Cancer cells were found to share the same expression of this distinct carbohydrate, termed oncofetal chondroitin sulfate on their surface. In this study we have used a protein conjugation system to produce a bispecific immune engager, V-aCD3, based on recombinant VAR2CSA as the cancer targeting moiety and an anti-CD3 single-chain variable fragment linked to a single-chain Fc as the immune engager. Conjugation of these two proteins resulted in a single functional moiety that induced immune mediated killing of a broad range of cancer cells in vitro and facilitated tumor arrest in an orthotopic bladder cancer xenograft model.<\/jats:p>","DOI":"10.1038\/s41419-021-03611-0","type":"journal-article","created":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T12:02:35Z","timestamp":1617710555000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Development of a bispecific immune engager using a recombinant malaria protein"],"prefix":"10.1038","volume":"12","author":[{"given":"Mie A.","family":"Nordmaj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan E.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie S.","family":"Sachse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5594-0716","authenticated-orcid":false,"given":"Robert","family":"Dagil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Poder","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanna","family":"Skeltved","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaare V.","family":"Grunddal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayit Mahmut","family":"Erdo\u011fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swati","family":"Choudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Gustsavsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maj Sofie","family":"\u00d8rum-Madsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Moskalev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2357-3947","authenticated-orcid":false,"given":"Weihua","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Clausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thor G.","family":"Theander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mads","family":"Daugaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2668-4992","authenticated-orcid":false,"given":"Morten A.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Salanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,6]]},"reference":[{"key":"3611_CR1","doi-asserted-by":"crossref","unstructured":"Brinkmann, U. & Kontermann, R. E. The making of bispecific antibodies. MAbs 9, 182\u2013212 (2017). https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/19420862.2016.1268307.","DOI":"10.1080\/19420862.2016.1268307"},{"key":"3611_CR2","doi-asserted-by":"crossref","unstructured":"Fan, G., Wang, Z., Hao, M. & Li, J. Bispecific antibodies and their applications. J. Hematol. Oncol. (2015). http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26692321.","DOI":"10.1186\/s13045-015-0227-0"},{"key":"3611_CR3","doi-asserted-by":"crossref","unstructured":"Krishnamurthy, A. & Jimeno, A. Bispecific antibodies for cancer therapy: a review. Pharmacol. Ther. 185, 122\u2013134, (2018). https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725817302930.","DOI":"10.1016\/j.pharmthera.2017.12.002"},{"key":"3611_CR4","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1182\/blood-2017-06-741058","volume":"131","author":"MP Velasquez","year":"2018","unstructured":"Velasquez, M. P., Bonifant, C. L. & Gottschalk, S. Redirecting T cells to hematological malignancies with bispecific antibodies. Blood 131, 30\u201338 (2018). http:\/\/www.bloodjournal.org\/lookup\/doi\/10.1182\/blood-2017-06-741058.","journal-title":"Blood"},{"key":"3611_CR5","doi-asserted-by":"crossref","unstructured":"Heiss, M. M. et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II\/III trial. Int. J. Cancer (2010). http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20473913.","DOI":"10.1002\/ijc.25423"},{"key":"3611_CR6","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","volume":"131","author":"N G\u00f6kbuget","year":"2018","unstructured":"G\u00f6kbuget, N. et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood 131, 1522\u20131531, (2018) http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29358182.","journal-title":"Blood"},{"key":"3611_CR7","unstructured":"Kantarjian, H. et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N. Engl. J. Med. (2017). http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28249141."},{"key":"3611_CR8","first-page":"870","volume":"39","author":"EV Chandrasekarar","year":"1979","unstructured":"Chandrasekarar, E. V. & Davidson, E. A. Glycosaminoglycans of normal and malignant cultured human mammary cells. Cancer Res. 39, 870\u2013880 (1979).","journal-title":"Cancer Res."},{"key":"3611_CR9","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nchembio810","volume":"2","author":"CI Gama","year":"2006","unstructured":"Gama, C. I. et al. Sulfation patterns of glycosaminoglycans encode molecular recognition and activity. Nat. Chem. Biol. 2, 467\u2013473 (2006).","journal-title":"Nat. Chem. Biol."},{"key":"3611_CR10","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/S0022-5347(17)47570-7","volume":"134","author":"DP De Klerk","year":"1985","unstructured":"De Klerk, D. P. The glycosaminoglycans of human bladder cancers of varying grade and stage. J. Urol. 134, 978\u2013981 (1985).","journal-title":"J. Urol."},{"key":"3611_CR11","doi-asserted-by":"publisher","unstructured":"Tarbell, J. M. & Cancel, L. M. The glycocalyx and its significance in human medicine. J. Int. Med. (2016). https:\/\/doi.org\/10.1111\/joim.12465.","DOI":"10.1111\/joim.12465"},{"key":"3611_CR12","doi-asserted-by":"crossref","unstructured":"De Klerk, D. P., Lee, D. V. & Human H. J. Glycosaminoglycans of human prostatic cancer. J. Urol. 131, 1008\u20131012 (1984).","DOI":"10.1016\/S0022-5347(17)50750-8"},{"key":"3611_CR13","unstructured":"Salanti A., et al. Targeting human cancer by a glycosaminoglycan binding malaria protein. Cancer Cell (2015). http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26461094."},{"key":"3611_CR14","doi-asserted-by":"crossref","unstructured":"Dahlb\u00e4ck, M. et al. The chondroitin sulfate A-binding site of the VAR2CSA protein involves multiple N-terminal domains. J. Biol. Chem. 286, 15908\u201315917 (2011).","DOI":"10.1074\/jbc.M110.191510"},{"key":"3611_CR15","doi-asserted-by":"publisher","first-page":"23332","DOI":"10.1074\/jbc.M112.348839","volume":"287","author":"TM Clausen","year":"2012","unstructured":"Clausen, T. M. et al. Structural and functional insight into how the Plasmodium falciparum VAR2CSA protein mediates binding to chondroitin sulfate A in placental malaria. J. Biol. Chem. 287, 23332\u201323345 (2012). http:\/\/www.jbc.org\/lookup\/doi\/10.1074\/jbc.M112.348839.","journal-title":"J. Biol. Chem."},{"key":"3611_CR16","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.sbsr.2016.05.003","volume":"9","author":"TM Clausen","year":"2016","unstructured":"Clausen, T. M. et al. Real-time and label free determination of ligand binding-kinetics to primary cancer tissue specimens; a novel tool for the assessment of biomarker targeting. Sens. Bio Sens. Res. 9, 23\u201330 (2016). http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27441183.","journal-title":"Sens. Bio Sens. Res."},{"key":"3611_CR17","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1158\/1541-7786.MCR-16-0103","volume":"14","author":"TM Clausen","year":"2016","unstructured":"Clausen, T. M. et al. Oncofetal chondroitin sulfate glycosaminoglycans are key players in integrin signaling and tumor cell motility. Mol. Cancer Res. 14, 1288\u20131299 (2016). http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27655130.","journal-title":"Mol. Cancer Res."},{"key":"3611_CR18","doi-asserted-by":"crossref","unstructured":"Agerb\u00e6k, M. \u00d8. et al. The VAR2CSA malaria protein efficiently retrieves circulating tumor cells in an EpCAM-independent manner. Nat. Commun. (2018). http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30115931.","DOI":"10.1038\/s41467-018-05793-2"},{"key":"3611_CR19","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.eururo.2017.03.021","volume":"72","author":"R Seiler","year":"2017","unstructured":"Seiler, R. et al. An oncofetal glycosaminoglycan modification provides therapeutic access to cisplatin-resistant bladder cancer. Eur. Urol. 72, 142\u2013150 (2017). https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283817302324.","journal-title":"Eur. Urol."},{"key":"3611_CR20","doi-asserted-by":"crossref","unstructured":"Mack, M., Riethmuller, G. & Kufer, P. A small bispecific antibody construct expressed as a functional single- chain molecule with high tumor cell cytotoxicity. Proc. Natl Acad. Sci. USA 92, 7021\u20137025 (1995).","DOI":"10.1073\/pnas.92.15.7021"},{"key":"3611_CR21","doi-asserted-by":"crossref","unstructured":"L\u00f6ffler, A. et al. A recombinant bispecific single-chain antibody, CD19 \u00d7 CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 95, 2098\u20132103 (2000).","DOI":"10.1182\/blood.V95.6.2098"},{"key":"3611_CR22","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1126\/science.1158545","volume":"321","author":"R Bargou","year":"2008","unstructured":"Bargou, R. et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321, 974\u2013977 (2008). http:\/\/www.sciencemag.org\/cgi\/doi\/10.1126\/science.1158545.","journal-title":"Science"},{"key":"3611_CR23","doi-asserted-by":"crossref","unstructured":"Hummel, H. D. et al. Phase 1 study of pasotuxizumab (BAY 2010112), a PSMA-targeting Bispecific T cell Engager (BiTE) immunotherapy for metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Oncol. 37, 5034 (2019).","DOI":"10.1200\/JCO.2019.37.15_suppl.5034"},{"key":"3611_CR24","doi-asserted-by":"crossref","unstructured":"Tabernero, J. et al. Phase Ia and Ib studies of the novel carcinoembryonic antigen (CEA) T-cell bispecific (CEA CD3 TCB) antibody as a single agent and in combination with atezolizumab: preliminary efficacy and safety in patients with metastatic colorectal cancer (mCRC). J. Clin. Oncol. 35, 3002 (2017).","DOI":"10.1200\/JCO.2017.35.15_suppl.3002"},{"key":"3611_CR25","doi-asserted-by":"crossref","unstructured":"Segal, N. H. et al. 403PPhase I studies of the novel carcinoembryonic antigen T-cell bispecific (CEA-CD3 TCB) antibody as a single agent and in combination with atezolizumab: preliminary efficacy and safety in patients (pts) with metastatic colorectal cancer (mCRC). Ann. Oncol. 28, v134 (2017).","DOI":"10.1093\/annonc\/mdx367.036"},{"key":"3611_CR26","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.cbpa.2013.03.029","volume":"17","author":"SR Frankel","year":"2013","unstructured":"Frankel, S. R. & Baeuerle, P. A. Targeting T cells to tumor cells using bispecific antibodies. Curr. Opin. Chem. Biol. 17, 385\u2013392 (2013). http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1367593113000549.","journal-title":"Curr. Opin. Chem. Biol."},{"key":"3611_CR27","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.tibtech.2014.08.001","volume":"32","author":"G Veggiani","year":"2014","unstructured":"Veggiani, G., Zakeri, B. & Howarth, M. Superglue from bacteria: unbreakable bridges for protein nanotechnology. Trends Biotechnol. 32, 506\u2013512 (2014). http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25168413.","journal-title":"Trends Biotechnol."},{"key":"3611_CR28","doi-asserted-by":"publisher","first-page":"E690","DOI":"10.1073\/pnas.1115485109","volume":"109","author":"B Zakeri","year":"2012","unstructured":"Zakeri, B. et al. Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin. Proc. Natl. Acad. Sci. USA 109, E690\u2013E697 (2012). http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22366317.","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"3611_CR29","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.cbpa.2015.10.002","volume":"29","author":"SC Reddington","year":"2015","unstructured":"Reddington, S. C. & Howarth, M. Secrets of a covalent interaction for biomaterials and biotechnology: SpyTag and SpyCatcher. Curr. Opin. Chem. Biol. 29, 94\u201399 (2015). https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1367593115001106.","journal-title":"Curr. Opin. Chem. Biol."},{"key":"3611_CR30","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1093\/jb\/mvx023","volume":"162","author":"K Yumura","year":"2017","unstructured":"Yumura, K. et al. Use of SpyTag\/SpyCatcher to construct bispecific antibodies that target two epitopes of a single antigen. J. Biochem. 162, 203\u2013210 (2017). http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28637250.","journal-title":"J. Biochem."},{"key":"3611_CR31","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1002\/eji.1830230924","volume":"23","author":"P Matthys","year":"1993","unstructured":"Matthys, P. et al. Modification of the anti-CD3-induced cytokine release syndrome by anti-interferon-\u03b3 or anti-interleukin-6 antibody treatment: protective effects and biphasic changes in blood cytokine levels. Eur. J. Immunol. 23, 2209\u20132216 (1993).","journal-title":"Eur. J. Immunol."},{"key":"3611_CR32","doi-asserted-by":"publisher","first-page":"5154","DOI":"10.1182\/blood-2013-02-485623","volume":"121","author":"DT Teachey","year":"2013","unstructured":"Teachey, D. T. et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 121, 5154\u20135157 (2013).","journal-title":"Blood"},{"key":"3611_CR33","first-page":"3321","volume":"127","author":"JN Brudno","year":"2016","unstructured":"Brudno, J. N. & Kochenderfer, J. N. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. Am. Soc. Hematol. 127, 3321\u20133330 (2016).","journal-title":"Blood. Am. Soc. Hematol."},{"key":"3611_CR34","doi-asserted-by":"publisher","unstructured":"Shimabukuro-Vornhagen, A. et al. Cytokine release syndrome. J. Immunother. Cancer 6, 56 (2018). https:\/\/doi.org\/10.1186\/s40425-018-0343-9.","DOI":"10.1186\/s40425-018-0343-9"},{"key":"3611_CR35","doi-asserted-by":"crossref","unstructured":"J\u00e4ger, W. et al. Minimally invasive establishment of murine orthotopic bladder xenografts. J. Vis. Exp. (2014). http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24561487.","DOI":"10.3791\/51123"},{"key":"3611_CR36","first-page":"1","volume":"8","author":"W J\u00e4ger","year":"2013","unstructured":"J\u00e4ger, W. et al. Ultrasound-guided intramural inoculation of orthotopic bladder cancer xenografts: a novel high-precision approach. PLoS ONE 8, 1\u201311 (2013).","journal-title":"PLoS ONE"},{"key":"3611_CR37","doi-asserted-by":"crossref","unstructured":"Szadvari, I., Krizanova, O. & Babula, P. Athymic nude mice as an experimental model for cancer treatment. Physiol. Res. 65, S441\u2013S453 (2016).","DOI":"10.33549\/physiolres.933526"},{"key":"3611_CR38","doi-asserted-by":"crossref","unstructured":"Yang, F., Wen, W. & Qin, W. Bispecific antibodies as a development platform for new concepts and treatment strategies. Int. J. Mol. (2016). Sci. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28036020.","DOI":"10.3390\/ijms18010048"},{"key":"3611_CR39","doi-asserted-by":"publisher","first-page":"775","DOI":"10.4161\/mabs.22271","volume":"4","author":"T List","year":"2012","unstructured":"List, T. & Neri, D. Biodistribution studies with tumor-targeting bispecific antibodies reveal selective accumulation at the tumor site. MAbs 4, 775\u2013783 (2012). http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23032949.","journal-title":"MAbs"},{"key":"3611_CR40","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.4049\/jimmunol.154.4.1852","volume":"154","author":"IA Haagen","year":"1995","unstructured":"Haagen, I. A., Geerars, A. J., Clark, M. R. & van de Winkel, J. G. Interaction of human monocyte Fc gamma receptors with rat IgG2b. A new indicator for the Fc gamma RIIa (R-H131) polymorphism. J. Immunol. 154, 1852\u20131860 (1995). http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/7836769.","journal-title":"J. Immunol."},{"key":"3611_CR41","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1054\/bjoc.2000.1237","volume":"83","author":"R Zeidler","year":"2000","unstructured":"Zeidler, R. et al. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br. J. Cancer 83, 261\u2013266 (2000). http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10901380.","journal-title":"Br. J. Cancer"},{"key":"3611_CR42","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1146\/annurev.iy.06.040188.003213","volume":"6","author":"H Clevers","year":"1988","unstructured":"Clevers, H., Alarcon, B., Wileman, T. & Terhorst, C. The T cell receptor\/CD3 complex: a dynamic protein ensemble. Annu. Rev. Immunol. 6, 629\u2013662 (1988).","journal-title":"Annu. Rev. Immunol."},{"key":"3611_CR43","doi-asserted-by":"crossref","unstructured":"Chelius, D. et al. mAbs Structural and functional characterization of the trifunctional antibody catumaxomab. MAbs (2010). http:\/\/www.tandfonline.com\/action\/journalInformation?journalCode=kmab20www.landesbioscience.commAbs.","DOI":"10.4161\/mabs.2.3.11791"},{"key":"3611_CR44","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.4161\/19420862.2014.975660","volume":"6","author":"MD Oberst","year":"2014","unstructured":"Oberst, M. D. et al. CEA\/CD3 bispecific antibody MEDI-565\/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas. MAbs 6, 1571\u20131584 (2014). http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25484061.","journal-title":"MAbs"},{"key":"3611_CR45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0094324","volume":"9","author":"H Shiheido","year":"2014","unstructured":"Shiheido, H., Chen, C., Hikida, M., Watanabe, T. & Shimizu, J. Modulation of the human T cell response by a novel non-mitogenic anti-CD3 antibody. PLoS ONE 9, e94324 (2014). http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24710513.","journal-title":"PLoS ONE"},{"key":"3611_CR46","first-page":"1589","volume":"13","author":"AB Cosimi","year":"1981","unstructured":"Cosimi, A. B. et al. Immunologic monitoring with monoclonal antibodies to human T-cell subsets. Transpl. Proc. 13, 1589\u20131593 (1981). http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/7029820.","journal-title":"Transpl. Proc."},{"key":"3611_CR47","unstructured":"Zeidler, R. et al. Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J. Immunol. 163, 1246\u20131252 (1999)."},{"key":"3611_CR48","unstructured":"Fouad, Y. A. & Aanei, C. Revisiting the hallmarks of cancer. Am. J. Cancer Res. 7, 1016\u20131036 (2017)."},{"key":"3611_CR49","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-Lostaov, L., Anel, A. & Pardo, J. How do cytotoxic lymphocytes kill cancer cells? Clin. Cancer Res. 21, 5047\u20135056 (2015).","DOI":"10.1158\/1078-0432.CCR-15-0685"},{"key":"3611_CR50","doi-asserted-by":"crossref","unstructured":"Yamada, A., Arakaki, R., Saito, M., Kudo, Y. & Ishimaru, N. Dual role of Fas \/ FasL-mediated signal in peripheral immune tolerance. Front. Immunol. 8 1\u201310 (2017).","DOI":"10.3389\/fimmu.2017.00403"},{"key":"3611_CR51","doi-asserted-by":"crossref","unstructured":"Tibbetts, M. D., Zheng, L. & Lenardo, M. J. The death effector domain protein family: regulators of cellular homeostasis. Nat. Immunol. 4, 8634\u20138644 (2003).","DOI":"10.1038\/ni0503-404"},{"key":"3611_CR52","doi-asserted-by":"crossref","unstructured":"Siegel, R. M., Chan, F. K., Chun, H. J., Lenardo, M. J. The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity. Nat. Immunol. 1, 469\u2013474 (2000).","DOI":"10.1038\/82712"},{"key":"3611_CR53","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.eururo.2017.10.003","volume":"73","author":"AM Kamat","year":"2018","unstructured":"Kamat, A. M. et al. Predicting response to intravesical Bacillus Calmette-Gu\u00e9rin immunotherapy: are we there yet? A systematic review. Eur. Urol. 73, 738\u2013748 (2018). https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283817308503.","journal-title":"Eur. Urol."},{"key":"3611_CR54","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg, J. E. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387, 1909\u20131920 (2016). http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26952546.","journal-title":"Lancet"},{"key":"3611_CR55","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","volume":"18","author":"P Sharma","year":"2017","unstructured":"Sharma, P. et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 18, 312\u2013322 (2017). http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28131785.","journal-title":"Lancet Oncol."},{"key":"3611_CR56","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","volume":"389","author":"AV Balar","year":"2017","unstructured":"Balar, A. V. et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 389, 67\u201376 (2017). http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27939400.","journal-title":"Lancet"},{"key":"3611_CR57","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt, J. et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N. Engl. J. Med. 376, 1015\u20131026 (2017). http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28212060.","journal-title":"N. Engl. J. Med."},{"key":"3611_CR58","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","volume":"391","author":"T Powles","year":"2018","unstructured":"Powles, T. et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 391, 748\u2013757 (2018). http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29268948.","journal-title":"Lancet"},{"key":"3611_CR59","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.juro.2017.10.041","volume":"199","author":"AO Siefker-Radtke","year":"2018","unstructured":"Siefker-Radtke, A. O., Apolo, A. B., Bivalacqua, T. J., Spiess, P. E. & Black, P. C. Immunotherapy with checkpoint blockade in the treatment of urothelial carcinoma. J. Urol. 199, 1129\u20131142 (2018). http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29113841.","journal-title":"J. Urol."},{"key":"3611_CR60","doi-asserted-by":"crossref","unstructured":"Sanmamed, M. F. et al. Nivolumab and urelumab enhance antitumor activity of human T lymphocytes engrafted in Rag2-\/-IL2R null immunodeficient mice. Cancer Res. (2015). http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26113085.","DOI":"10.1158\/1538-7445.AM2015-261"},{"key":"3611_CR61","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1182\/blood-2004-07-2561","volume":"105","author":"KF May","year":"2004","unstructured":"May, K. F. et al. Anti-human CTLA-4 monoclonal antibody promotes T-cell expansion and immunity in a hu-PBL-SCID model: a new method for preclinical screening of costimulatory monoclonal antibodies. Blood 105, 1114\u20131120 (2004). http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15486062.","journal-title":"Blood"},{"key":"3611_CR62","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1007\/s00262-012-1237-1","volume":"61","author":"TS Fisher","year":"2012","unstructured":"Fisher, T. S. et al. Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity. Cancer Immunol. Immunother. 61, 1721\u20131733 (2012). http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22406983.","journal-title":"Cancer Immunol. Immunother."},{"key":"3611_CR63","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.it.2018.07.001","volume":"39","author":"P De La Rochere","year":"2018","unstructured":"De La Rochere, P. et al. Humanized mice for the study of immuno-oncology. Trends Immunol. 39, 748\u2013763 (2018). https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S147149061830125X.","journal-title":"Trends Immunol."},{"key":"3611_CR64","doi-asserted-by":"publisher","first-page":"626","DOI":"10.3174\/ajnr.A2054","volume":"31","author":"W Bou-Assaly","year":"2010","unstructured":"Bou-Assaly, W. & Mukherji, S. Cetuximab (erbitux). AJNR Am. J. Neuroradiol. 31, 626\u2013627 (2010). http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20167650.","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"3611_CR65","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2147\/OTT.S3842","volume":"1","author":"AK Koutras","year":"2008","unstructured":"Koutras, A. K. & Evans, T. R. J. The epidermal growth factor receptor family in breast cancer. Onco Targets Ther. 1, 5\u201319 (2008). http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21127748.","journal-title":"Onco Targets Ther."},{"key":"3611_CR66","first-page":"3639","volume":"23","author":"S Yano","year":"2003","unstructured":"Yano, S. et al. Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition. Anticancer Res. 23, 3639\u20133650 (2003). http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/14666659.","journal-title":"Anticancer Res."},{"key":"3611_CR67","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1677\/erc.1.00766","volume":"11","author":"P Carter","year":"2004","unstructured":"Carter, P., Smith, L. & Ryan, M. Identification and validation of cell surface antigens for antibody targeting in oncology. Endocr. Relat. Cancer 11, 659\u2013687 (2004). http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15613445.","journal-title":"Endocr. Relat. Cancer"},{"key":"3611_CR68","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.tibtech.2015.02.008","volume":"33","author":"D S\u00e1nchez-Mart\u00edn","year":"2015","unstructured":"S\u00e1nchez-Mart\u00edn, D. et al. Selection strategies for anticancer antibody discovery: searching off the beaten path. Trends Biotechnol. 33, 292\u2013301 (2015). http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25819764.","journal-title":"Trends Biotechnol."},{"key":"3611_CR69","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1002\/ijc.26258","volume":"130","author":"MG Ott","year":"2012","unstructured":"Ott, M. G. et al. Humoral response to catumaxomab correlates with clinical outcome: Results of the pivotal phase II\/III study in patients with malignant ascites. Int. J. Cancer 130, 2195\u20132203 (2012). http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21702044.","journal-title":"Int. J. Cancer"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-03611-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-03611-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-03611-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T18:33:51Z","timestamp":1698863631000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-03611-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,6]]},"references-count":69,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,4]]}},"alternative-id":["3611"],"URL":"https:\/\/doi.org\/10.1038\/s41419-021-03611-0","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,6]]},"assertion":[{"value":"24 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.S., T.T., M.A.N., T.M.C., and M.D. have shares in VAR2Pharmaceuticals who owns the rights to use rVAR2 for diagnosing and treating cancer. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All animal experiments performed in accordance with the University of British Columbia Animal Care Committee and the Canadian Council of Animal Care guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}}],"article-number":"353"}}